GlucoTrack (NASDAQ: GCTK) has outlined plans to pursue U.S. regulatory clearance for its glucose monitoring device, a development that quickly boosted investor sentiment.
Specifically, the company announced it intends to submit an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026.
Following this update, the market reacted quickly. Shares climbed over 30% in pre-market trading on Friday. Even so, the stock remains far below earlier levels. It is still down more than 93% from its 52-week high of $15.90, recorded on June 25, 2025.
Early Clinical Results Support Momentum
The renewed investor interest comes alongside encouraging clinical progress.
GlucoTrack recently completed its first human study in Brazil, conducted between December 2024 and January 2025 at the cardiology research center in São Paulo. The study enrolled a small cohort of 10 adults living with either Type 1 or Type 2 diabetes and evaluated the performance of an intravascular glucose monitoring device connected to external electronics.
Notably, results from the five-day study were promising. The system achieved a Mean Absolute Relative Difference (MARD) of 7.7% based on 122 matched readings, alongside a 99% data capture rate. Importantly, no device-related serious adverse events were reported, and both primary and secondary endpoints were met.
Building on these findings, the company initiated a follow-up study in July 2025 at St Vincent’s Hospital in Melbourne. According to GlucoTrack, performance in this trial closely mirrored the earlier results while also providing insights to refine study protocols and device design.
Next Step: U.S. Trials and FDA Engagement
With encouraging early data in hand, GlucoTrack is now preparing for its next phase of development.
To that end, the company has secured a U.S. clinical trial site and partnered with a Clinical Research Organization specializing in diabetes medical technology. It plans to begin its U.S. trial in H2 2026, contingent on FDA approval of its IDE application.
At the same time, GlucoTrack has strengthened its intellectual property portfolio. The U.S. Patent and Trademark Office granted three patents in late 2025, covering sensor chemistry, intravascular lead design, and low-power electronics—key components of its technology platform.
Technology Targets Real-Time Accuracy
Beyond regulatory progress, GlucoTrack continues to emphasize the potential advantages of its system.
Unlike traditional continuous glucose monitors that rely on interstitial fluid, the company’s device measures glucose directly from blood. This approach is designed to eliminate the lag time commonly associated with existing technologies.
Additionally, the device is intended for long-term use, with an expected functional lifespan of up to three years. If achieved, this could offer a meaningful convenience advantage for patients requiring continuous monitoring.
Financial Constraints Remain in Focus
However, despite these advancements, GlucoTrack (NASDAQ: GCTK) faces ongoing financial challenges.
The company’s market capitalization is approximately $1.55 million, with shares trading near $1.42. Over the past 12 months, it has reported a negative EBITDA of $16.38 million, reflecting continued operational losses and significant cash burn.
However, the company maintains more cash than debt, providing a degree of short-term financial flexibility as it advances its development plans.
Market Strategy and Manufacturing Plans
Even amid financial pressure, GlucoTrack is laying the groundwork for commercialization.
CEO Paul V. Goode stated that the company has completed U.S. market research and identified a viable reimbursement pathway. In parallel, it has established a dual-source manufacturing strategy in the United States. This strategy involves engaging two contract manufacturers to support future production.
Taken together, GlucoTrack is advancing on multiple fronts—from clinical validation and regulatory preparation to intellectual property and manufacturing readiness. While financial risks remain, the company’s upcoming FDA submission represents a critical inflection point that could shape its trajectory in the years ahead.
